Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Cabaletta Bio, Inc. (CABA) shareholder Bain Capital Life Sciences Opportunities III, L.P. reported holding 15,209,188 common shares and a pre-funded warrant to purchase up to 6,000,000 additional shares as of September 30, 2026. The reported aggregate beneficial ownership was 21,209,188 shares, or 9.57%, with shared voting and dispositive power over that amount.
The 9.57% calculation used 215,720,392 CABA shares outstanding as of October 30, 2026, plus the 6,000,000 shares issuable under the warrant. The warrant cannot be exercised if doing so would cause the holder to beneficially own more than 9.99% of the shares then issued and outstanding immediately after exercise.
Key Figures
Common shares held:15,209,188 sharesPre-funded warrant:Up to 6,000,000 sharesAggregate beneficial ownership:21,209,188 shares+3 more
6 metrics
Common shares held15,209,188 sharesHeld by Bain Capital Life Sciences Opportunities III, L.P. as of September 30, 2026
Pre-funded warrantUp to 6,000,000 sharesShares purchasable under the warrant held as of September 30, 2026
Aggregate beneficial ownership21,209,188 sharesReported by Bain Capital Life Sciences Opportunities III, L.P.
Percent of class9.57%Reported ownership percentage
Beneficial-ownership limit9.99%Maximum resulting ownership permitted for warrant exercise under the stated restriction
CABA shares outstanding215,720,392 sharesAs of October 30, 2026; used in the reported ownership-percentage calculation
Key Terms
pre-funded warrant, beneficially own, shared voting power, shared dispositive power
4 terms
pre-funded warrantfinancial
"a pre-funded warrant to purchase up to 6,000,000 shares"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
beneficially ownregulatory
"beneficially own more than 9.99% of the total number of shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting powerregulatory
"Shared Voting Power 21,209,188.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power 21,209,188.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many CABA shares did Bain Capital Life Sciences Opportunities III report?
It reported holding 15,209,188 common shares and a pre-funded warrant to purchase up to 6,000,000 shares. Its reported aggregate beneficial ownership was 21,209,188 shares, or 9.57%.
What restriction applies to the CABA pre-funded warrant?
The holder cannot exercise the warrant if the exercise would cause it to beneficially own more than 9.99% of CABA’s shares issued and outstanding immediately after exercise.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
CABALETTA BIO, INC.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
12674W109
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
12674W109
1
Names of Reporting Persons
Bain Capital Life Sciences Opportunities III, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,209,188.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,209,188.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,209,188.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.57 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CABALETTA BIO, INC.
(b)
Address of issuer's principal executive offices:
2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities III, L.P., a Delaware limited partnership (the "Reporting Person").
Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.
(b)
Address or principal business office or, if none, residence:
The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.
(c)
Citizenship:
Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.
(d)
Title of class of securities:
Common Stock, $0.00001 par value per share
(e)
CUSIP No.:
12674W109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on September 30, 2026, the Reporting Person held 15,209,188 shares of Common Stock and a pre-funded warrant to purchase up to 6,000,000 shares of Common Stock. The Reporting Person is prohibited from exercising the pre-funded warrant to purchase Common Stock if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise.
The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on (i) 215,720,392 shares of Common Stock outstanding as of October 30, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026 and (ii) 6,000,000 shares of Common Stock issuable upon the exercise of the pre-funded warrant held by the Reporting Person.
(b)
Percent of class:
See Item 4(a) hereof.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
See Item 4(a) hereof.
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
See Item 4(a) hereof.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Bain Capital Life Sciences Opportunities III, LP
Signature:
/s/ Andrew Hack
Name/Title:
Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC